Research Library › Neuropeptides
PT-141 is the original development code for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist and was derived from Melanotan II. It was developed by Palatin Technologies of New Jersey from a University of Arizona peptide line, with the name entering the MeSH database in 2003. As of October 2026 bremelanotide is FDA-approved only as the prescription product Vyleesi (2019); products sold as “PT-141” are not approved drugs.
Key facts
| Type | Synthetic cyclic heptapeptide; analog of alpha-MSH |
|---|---|
| Other names | Bremelanotide (INN), PT-141; brand Vyleesi |
| Developed by | Palatin Technologies, building on Melanotan II from the University of Arizona |
| First described | Early 2000s as PT-141 (MeSH entry 2003); derived from Melanotan II (1989 design) |
| Designed target | Melanocortin receptors, activated non-selectively (MC1R, MC4R, MC3R, MC5R, MC2R in order of potency per FDA label) |
| Regulatory status (Oct 2026) | FDA-approved only as Vyleesi (June 2019); other "PT-141" products unapproved and named in FDA warning letters (Aug 2026) |
Who developed it
Bremelanotide was developed by Palatin Technologies of Cranbury, New Jersey, under the code PT-141 [2]. It descends from the melanocortin peptides created at the University of Arizona by Victor Hruby, Mac Hadley and Robert Dorr. In a 2006 review, Hadley and Dorr described PT-141 as a newer analog of Melanotan II developed by Palatin, and disclosed royalties from Palatin received through a Competitive Technologies agreement with the university [1].
Palatin licensed North American rights to AMAG Pharmaceuticals in January 2017. AMAG held the New Drug Application when the FDA approved the drug in 2019 [4]. The licence was ended in July 2020, returning the rights to Palatin [5], and in December 2023 Palatin completed the sale of Vyleesi to Cosette Pharmaceuticals [6].
Structure and design
The FDA label describes bremelanotide acetate as a synthetic cyclic heptapeptide with an acetylated amino terminus and a free acid at the carboxyl terminus: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys-OH). Its free-base molecular weight is about 1,025 daltons [3].
That ring structure is shared with Melanotan II, which ends in an amide instead of a free acid. A 2007 review called Melanotan II the parent compound from which bremelanotide was derived [2]. The label classifies bremelanotide as a non-selective melanocortin receptor agonist and states that its mechanism of action for its approved indication is unknown [3].
Earlier descriptions focused on two receptor subtypes expressed in the brain. The National Library of Medicine’s MeSH record describes bremelanotide as a synthetic alpha-MSH analog that is an agonist at melanocortin receptors including MC3R and MC4R, and the 2007 review characterized it the same way [2, 7]. These statements describe receptor binding, not effects in people.
Research history
- 1990s: Melanotan II, the parent peptide, is studied at the University of Arizona [1]
- 2003: Bremelanotide (PT-141) entered in the National Library of Medicine’s MeSH vocabulary [7]
- 2006-2007: Reviews describe PT-141 completing Phase I/II studies at Palatin, with Phase III planned [1, 2]
- January 2017: Palatin licenses North American rights to AMAG Pharmaceuticals [4]
- June 2019: FDA approves Vyleesi (bremelanotide injection) [4]
- July 2020: AMAG licence terminated; rights return to Palatin [5]
- December 2023: Palatin completes sale of Vyleesi to Cosette Pharmaceuticals [6]
Regulatory status as of October 2026
The FDA approved Vyleesi (bremelanotide injection) in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [3, 4]. That approval covers only the labeled prescription product.
Products sold online as “PT-141” are not FDA-approved and are not equivalent to Vyleesi. In August 2026 the FDA issued warning letters to several online sellers of peptides labeled “research use only,” and PT-141/bremelanotide was among the products named [8].
About this reference page
Kalibra Labs does not currently supply PT-141 (bremelanotide). This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Is PT-141 the same as bremelanotide?
Yes. PT-141 was Palatin Technologies’ development code for the peptide that received the international nonproprietary name bremelanotide [2, 7].
Is PT-141 FDA approved?
Bremelanotide is FDA-approved only as Vyleesi, a prescription injection approved in 2019. Other products sold as PT-141 are not FDA-approved [3, 4, 8].
Who developed PT-141?
Palatin Technologies developed it from Melanotan II, a peptide created at the University of Arizona [1, 2].
How is PT-141 related to Melanotan II?
Bremelanotide shares Melanotan II’s cyclic seven-residue structure but ends in a free acid instead of an amide; a 2007 review described Melanotan II as its parent compound [2, 3].
Who owns Vyleesi now?
Palatin completed the sale of Vyleesi to Cosette Pharmaceuticals in December 2023 [6].
Sources
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. Link
- Bridges TM. Molecule of the month: bremelanotide. Curr Top Med Chem. 2007;7(11):1152. doi:10.2174/156802607780906582. Link
- U.S. FDA. VYLEESI (bremelanotide injection), prescribing information (FDALabel), NDA 210557; initial U.S. approval 2019. Link
- Palatin Technologies. FDA approves New Drug Application for Vyleesi (bremelanotide injection). Press release (SEC Form 8-K, Exhibit 99.1), 21 Jun 2019. Link
- Palatin Technologies. Palatin regains North American rights to Vyleesi from AMAG Pharmaceuticals. Press release (SEC Form 8-K, Exhibit 99.1), 27 Jul 2020. Link
- Palatin Technologies. Palatin completes sale of Vyleesi to Cosette Pharmaceuticals. Press release, 20 Dec 2023. Link
- National Library of Medicine. MeSH supplementary concept record: bremelanotide (C476721), entry terms PT-141 and Vyleesi; date introduced 28 Aug 2003. Link
- ArentFox Schiff. RUO-ined: Five peptide vendors learn that 'research use only' is not a legal strategy. 18 Sep 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
